搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Impacts
9 小时
Eczema on lips can be painful and distressing
Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...
来自MSN
20 小时
Atopic dermatitis market to reach $16.7b by 2030 across seven major markets
Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
Lianhe Zaobao
12 天
止不住的瘙痒 异位性皮肤炎怎么控制?
异位性皮肤炎不仅会伤害患者的皮肤,也可能影响生活质量和日常活动。新加坡中央医院将在9月13日(星期五)举办“异位性皮肤炎——不止是皮肤表层问题”(Atopic Dermatitis – More than skin deep?)线上英语讲座。
Everyday Health
3 天
Ebglyss, a New Biologic Treatment for Atopic Dermatitis, Gets FDA Approval
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
6 天
康健园 | 世界特应性皮炎日:抹掉“社交滤镜”,以无暇肌肤实现 ...
在社交媒体光鲜滤镜的背后,许多饱受特应性皮炎困扰的患者往往会通过“精修”的图片来“隐藏”皮肤问题,而他们在日常生活中遭受的挑战也常被公众忽视和误解。作为皮肤科的“一号疾病”,特应性皮炎(Atopic Dermatitis,简称“AD”)具有遗传性和家族史的特征,属于免疫介导炎症性疾病(简称IMID),我国现有高达3000万人深受其扰,主要表现为湿疹样皮疹和难以忍受的剧烈瘙痒。
dermatologyadvisor
12 小时
Pediatric Atopic Dermatitis: Dupilumab Normalizes Inflammatory Biomarkers
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
GlobalData on MSN
2 天
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...
The Pharma Letter
1 天
Atopic dermatitis market set for major growth
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
1 天
FDA approves Ebglyss for moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
1 天
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
中国网
6 天
与患者联手,共享美好生活 ——北京大学人民医院开展“世界特应性 ...
中国网9月14日讯(记者王一辰)9 月 14 日是第七个的“世界特应性皮炎日” (World Atopic Dermatitis ...
The American Journal of Managed Care
4 天
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic ...
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈